Chronic Hepatitis B Current Drugs and Indications for Treatment

BETH RUIZ, MPAS, PA-C TRANSPLANT HEPATOLOGY UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER METHODIST TRANSPLANT INSTITUTE

Case

35 year old male who presents with chronic hepatitis B

Labs

- $\blacktriangleright \text{HBsAg+} \geq 6 \text{ months, HBeAg+}$
- ▶ HBV DNA >1,000,000 IU/mL
- ▶ ALT < 35 U/L
- Platelet count within normal limits
- ▶ Fibroscan F0/1
- ▶ US abdomen no cirrhosis

Patient would like to discuss possible treatment options


Chronic Hepatitis B

► HBsAg present \geq 6 months

- HBV viral load ranges from undetectable up to billions
- HBeAg, HBeAb status helps determine immune phase
- ALT level normal to elevated
- Liver biopsy/non invasive tests (chronic hepatitis, variable necroinflammation with/without fibrosis)

Non Invasive Testing

- Serum panels (Fibrosure, FIB-4, APRI)
- Elastography more accurate however can overestimate fibrosis with high levels of necroinflammation (high ALT levels)
- AASLD 2018 guidelines ULN ALT 25 U/L women and 35 U/L men



Immune Tolerant

- Endemic regions (Asia, Sub-Saharan Africa)
- > 90% perinatal transmission cases will develop CHB
- HBeAg+ with HBV DNA very high >1 million IU/mL
- Normal or minimally elevated ALT
- Liver biopsy/non invasive tests show minimal inflammation and no fibrosis
- No treatment
- Monitor labs every 3 6 months

Why no treatment for Immune Tolerant?

- Estimated 30 years until reach immune active phase requiring treatment
- Immune system is "tolerant" to virus
- Do not respond well to antivirals
- Less likely to see HBeAg seroconversion, HBsAg loss unlikely
- High rate viral replication takes longer for viral load decline
- Concerns for long term SE medications and future antiviral resistance

Reasons to treat Immune Tolerant

- >40 years of age with persistent normal/borderline ALT and HBV DNA >20,000 IU/mL consider liver biopsy and treat for <u>> F2</u>
- Other factors to consider:
 - Strong FH cirrhosis/HCC
 - Previous antiviral treatment

Antivirals

PEG Interferon Alpha 2a

- Finite treatment (48 weeks)
- ► HBV/HDV
- Contraindicated pregnancy, decompensated cirrhosis
- Side effects not well tolerated

Entecavir

- Decompensated cirrhosis increase dose 1mg
- Viral potency
- Avoid with previous lamivudine resistance

Antivirals

Tenofovir disoproxil fumarate (TDF)

- Pregnant women 3rd trimester HBV DNA >200,000 to prevent perinatal transmission
- Concerns for increased renal toxicity and BMD loss (switch to entecavir or TAF)

Tenofovir alafenamide (TAF)

- Prior treatment or antiviral resistance
- ► HIV/HBV
- Less renal and bone toxicity concerns than TDF

Antiviral resistance

- Avoid monotherapy with lamivudine, adefovir, or telbivudine due to high risk of drug resistance
- Check medication adherence
- High HBV DNA level takes longer time for HBV DNA level to become undetectable *Recommended to continue same monotherapy dose and monitor declining HBV DNA levels

Case

- Plan to continue to monitor every 3 6 months with labs (HBsAg, HBeAg, anti-HBe, HBV DNA viral load, ALT, Fibrosis testing)
- Start treatment for ALT >2xULN, \geq F2, cirrhosis
- >40 years of age consider liver biopsy and start treatment for \geq F2
- HCC screening (US every 6 months +/- AFP)

Conclusion

Who to treat with CHB

- Cirrhosis, refer to specialist/transplant center
- Active immune phases
- \blacktriangleright 2 F2 fibrosis
- Decision to treat case by case, other factors (age, FH, previous antiviral treatment)
- When in doubt consider liver biopsy

What we can do to help decrease prevalence HBV

- Universal one-time screening adults \geq 18 years
- Universal vaccination adults 19 59 years

Thank you!